United States securities and exchange commission logo





                              July 6, 2023

       David Happel
       President and Chief Executive Officer
       Sagimet Biosciences Inc.
       155 Bovet Road, Suite 303
       San Mateo, California 94402

                                                        Re: Sagimet Biosciences
Inc.
                                                            Amendment No. 1 to
Registration Statement on Form S-1
                                                            Filed July 3, 2023
                                                            Registration
Statement on Form S-1
                                                            Filed June 23, 2023
                                                            File No. 333-272901

       Dear David Happel:

             We have reviewed your amended registration statement and have the
following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 1 to Registration Statement on Form S-1

       Business
       Data for selected competitor product candidates, page 120

   1.                                                   We note your revised
disclosure on pages 120-121 which presents data from multiple
                                                        other clinical drug
candidates for the treatment of NASH. Given that you do not appear to
                                                        have conducted
head-to-head trials of your product candidate against any of the product
                                                        candidates included in
this disclosure, the inclusion of this information does not appear to
                                                        be appropriate. Please
remove this disclosure from the prospectus. You may cite
                                                        competitor product
candidates without presenting data from competitor clinical trials.
 David Happel
Sagimet Biosciences Inc.
July 6, 2023
Page 2
License agreement with Ascletis, page 121

2.    We note your disclosure indicating that in July 2023 you assigned
additional patents and
      patent applications to Gannex. Please revise your disclosure to disclose
the subject matter
      of the additional patents and patent applications assigned to Gannex.
Exhibits

3.    We note that Exhibit 10.24 appears to contain redactions. Please revise
your exhibit index
      to disclose that this exhibit contains redactions. Please also file the
July 2023 Assignment
      and Assumption Agreement referenced on page 122 as an exhibit to your
registration
      statement. Alternatively, please tell us why this agreement is not
required to be filed.
       You may contact Gary Newberry at 202-551-3761 or Angela Connell at
202-551-3426 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Cindy Polynice at 202-551-8707 or Alan Campbell at 202-551-4224 with
any other
questions.



                                                            Sincerely,
FirstName LastNameDavid Happel
                                                            Division of
Corporation Finance
Comapany NameSagimet Biosciences Inc.
                                                            Office of Life
Sciences
July 6, 2023 Page 2
cc:       Alicia Tschirhart
FirstName LastName